ONTX Onconova Therapeutics, Inc. Stock Quote

ONTX [NASD]

Index	-	P/E	-	EPS (ttm)	-1.33	Insider Own	0.20%	Shs Outstand	15.98M	Perf Week	-16.72%
Market Cap	60.40M	Forward P/E	-	EPS next Y	-1.05	Insider Trans	44.51%	Shs Float	14.81M	Perf Month	-28.07%
Income	-18.80M	PEG	-	EPS next Q	-0.27	Inst Own	17.50%	Short Float	2.35%	Perf Quarter	-49.43%
Sales	0.20M	P/S	302.02	EPS this Y	90.30%	Inst Trans	39.42%	Short Ratio	0.17	Perf Half Y	-61.12%
Book/sh	3.11	P/B	0.85	EPS next Y	8.50%	ROA	-43.50%	Target Price	11.50	Perf Year	-45.07%
Cash/sh	2.60	P/C	1.02	EPS next 5Y	-	ROE	-59.80%	52W Range	2.69 - 28.95	Perf YTD	-62.22%
Dividend	-	P/FCF	-	EPS past 5Y	-	ROI	-403.20%	52W High	-90.88%	Beta	1.72
Dividend %	-	Quick Ratio	8.50	Sales past 5Y	-54.20%	Gross Margin	-	52W Low	-1.86%	ATR	0.21
Employees	11	Current Ratio	8.50	Sales Q/Q	0.00%	Oper. Margin	-	RSI (14)	30.17	Volatility	9.12% 6.53%
Optionable	Yes	Debt/Eq	0.00	EPS Q/Q	58.20%	Profit Margin	-	Rel Volume	0.25	Prev Close	2.89
Shortable	Yes	LT Debt/Eq	0.00	Earnings	Nov 11 AMC	Payout	-	Avg Volume	2.02M	Price	2.64
Recom	2.00	SMA20	-19.11%	SMA50	-25.08%	SMA200	-66.14%	Volume	496,586	Change	-8.65%

May-18-21

Initiated

Guggenheim

Buy

Mar-01-18

Reiterated

H.C. Wainwright

Buy

$6 → $7.50

Jan-17-18

Downgrade

Maxim Group

Buy → Hold

Oct-09-17

Initiated

H.C. Wainwright

Buy

Apr-27-17

Initiated

Laidlaw

Buy

$10

Jul-01-15

Upgrade

Piper Jaffray

Neutral → Overweight

May-05-15

Initiated

H.C. Wainwright

Buy

Dec-02-21 08:00AM	Onconova Therapeutics Announces the Presentation of Preliminary Clinical Data Providing Evidence of Rigosertibs Activity in RDEB-associated Squamous Cell Carcinoma GlobeNewswire +5.47%
Nov-22-21 08:00AM	Onconova Therapeutics to Present at the Piper Sandler 33rd Annual Virtual Healthcare Conference GlobeNewswire
Nov-11-21 04:01PM	Onconova Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business Update GlobeNewswire
Nov-04-21 03:01PM	Onconova Therapeutics, Inc. (ONTX) May Report Negative Earnings: Know the Trend Ahead of Q3 Release Zacks
08:00AM	Onconova Therapeutics to Provide Corporate Update and Announce Third Quarter 2021 Financial Results on November 11, 2021 GlobeNewswire
Oct-01-21 12:35PM	Lab notes: Onconova completes $21M stock sale; Waypoint gets $1.7M investment American City Business Journals
Sep-29-21 08:00AM	Onconova Therapeutics to Attend the Sachs 21st Annual Biotech in Europe Forum (BEF) GlobeNewswire
Sep-28-21 04:05PM	Onconova Therapeutics, Inc. Announces Closing of $21 Million Public Offering of Common Stock GlobeNewswire
Sep-24-21 12:13PM	Mid-Day Market Update: Aehr Test Systems Surges Following Q1 Results; Onconova Therapeutics Shares Slide Benzinga -20.94%
10:29AM	Mid-Morning Market Update: Markets Mixed; Nike Sales Miss Views Benzinga
09:24AM	Onconova Therapeutics Raises $21M Via Equity At 17% Discount Benzinga
08:30AM	Is the Options Market Predicting a Spike in Onconova (ONTX) Stock? Zacks
08:00AM	Onconova Therapeutics, Inc. Announces Pricing of $21 Million Public Offering of Common Stock GlobeNewswire
Sep-23-21 04:01PM	Onconova Therapeutics, Inc. Announces Proposed Public Offering of Common Stock GlobeNewswire -18.89%
10:18AM	Onconova (ONTX) KRAS Inhibitor Shows Activity in Lung Cancer Zacks
Sep-22-21 03:15PM	Mid-Afternoon Market Update: Dow Surges Over 400 Points; Stitch Fix Shares Spike Higher Benzinga +28.57%
08:00AM	Onconova Therapeutics Announces Encouraging Clinical Data Supporting the Anti-Cancer Activity of Rigosertib-Nivolumab Combination in Advanced KRAS+ Non-Small Cell Lung Cancer GlobeNewswire
Sep-20-21 08:00AM	Onconova Therapeutics Announces Upcoming Presentation at the 3rd Annual RAS Targeted Drug Development Summit GlobeNewswire -7.63%
Sep-09-21 08:00AM	Onconova Therapeutics Announces Participation at the Upcoming H.C. Wainwright 23rd Annual Global Investment Conference GlobeNewswire
Aug-12-21 07:25PM	Onconova Therapeutics, Inc. (ONTX) Reports Q2 Loss, Tops Revenue Estimates Zacks
04:05PM	Onconova Therapeutics Reports Second Quarter 2021 Financial Results and Provides Business Update GlobeNewswire
Aug-05-21 08:00AM	Onconova Therapeutics to Provide Corporate Update and Announce Second Quarter 2021 Financial Results on August 12, 2021 GlobeNewswire
Aug-04-21 03:00PM	Will Onconova Therapeutics, Inc. (ONTX) Report Negative Q2 Earnings? What You Should Know Zacks
Jun-28-21 08:00AM	Onconova Therapeutics Provides an Update on the Phase 1/2a Trial of Rigosertib-Nivolumab Combination in KRAS+ Non-Small Cell Lung Cancer GlobeNewswire
Jun-22-21 08:00AM	Onconova Therapeutics Regains Compliance with Nasdaq Continued Listing Requirement GlobeNewswire
Jun-17-21 08:00AM	Onconova Therapeutics Announces the Peer-Reviewed Publication of Preclinical Data Demonstrating the Synergistic Anti-Cancer Activity of Rigosertib Combined with Immune Checkpoint Blockade GlobeNewswire
Jun-10-21 08:00AM	Onconova Therapeutics Announces Participation in A.G.P.s Upcoming Virtual Summer Healthcare Symposium GlobeNewswire
Jun-04-21 12:00PM	Onconova Therapeutics, Inc. (ONTX) Upgraded to Buy: What Does It Mean for the Stock? Zacks
Jun-03-21 08:00AM	Onconova Therapeutics Announces Upcoming Presentation at 2021 BIO Digital GlobeNewswire -6.13%
Jun-01-21 08:00AM	Onconova Therapeutics Announces the Appointment of Mark Gelder, M.D., as Chief Medical Officer GlobeNewswire
May-21-21 08:00AM	Onconova Therapeutics Announces the Initial Dosing of the First Patient in the U.S. Phase 1 Clinical Trial of ON 123300 GlobeNewswire -15.71%
May-20-21 08:32AM	Onconova Therapeutics Announces Reverse Stock Split and Decrease in Authorized Shares GlobeNewswire -21.08%
May-17-21 04:05PM	Onconova Therapeutics Reports First Quarter 2021 Financial Results and Provides Business Update GlobeNewswire +17.30%
02:45PM	Onconova Therapeutics, Inc. to Host Earnings Call ACCESSWIRE
May-14-21 10:25AM	7 Reddit Penny Stocks Promising to Cure Cancer InvestorPlace
May-10-21 08:00AM	Onconova Therapeutics to Provide Corporate Update and Announce First Quarter 2021 Financial Results on May 17, 2021 GlobeNewswire -8.37%
May-06-21 03:01PM	Onconova Therapeutics, Inc. (ONTX) May Report Negative Earnings: Know the Trend Ahead of Q1 Release Zacks
Apr-22-21 08:00AM	Onconova Announces First Patient Dosed in Investigator-Initiated Phase 2 Study of Rigosertib in Recessive Dystrophic Epidermolysis Bullosa-Associated Squamous Cell Carcinoma GlobeNewswire +21.63%
Apr-01-21 08:00AM	Onconova Therapeutics Announces Enrollment in Second Cohort of Phase 1 Study with ON 123300 in China GlobeNewswire -5.01%
Mar-29-21 08:00AM	Onconova to Present at the Spring 2021 Oncology Investor Conference GlobeNewswire -5.11%
Mar-11-21 04:05PM	Onconova Therapeutics Reports Full Year 2020 Financial Results, Provides Business Update GlobeNewswire
02:30PM	Onconova Therapeutics, Inc. to Host Earnings Call ACCESSWIRE
Mar-04-21 04:15PM	Onconova Therapeutics to Provide Corporate Update and Full Year 2020 Financial Results GlobeNewswire -18.53%
Mar-01-21 08:00AM	Onconova Therapeutics to Participate in Three Investment Conferences During the Month of March GlobeNewswire
Feb-24-21 08:00AM	Onconova Therapeutics Regains Compliance with Nasdaq Continued Listing Requirement GlobeNewswire
Feb-22-21 09:47AM	5 Value Stocks In The Healthcare Sector Benzinga
Feb-17-21 05:51PM	Why Onconova Therapeutics Stock Soared Today Motley Fool +23.77%
Feb-16-21 04:03PM	Onconova Therapeutics, Inc. Announces Closing of $28.75 Million Public Offering of Common Stock Including Full Exercise of the Over-Allotment Option GlobeNewswire +5.17%
08:00AM	Onconova Therapeutics to Present Corporate Update at the 2021 BIO CEO & Investor Digital Conference GlobeNewswire
Feb-10-21 10:49PM	Onconova Therapeutics, Inc. Announces Pricing of $25 Million Public Offering of Common Stock GlobeNewswire
04:01PM	Onconova Therapeutics, Inc. Announces Proposed Public Offering of Common Stock GlobeNewswire
Feb-04-21 11:54AM	Return On Capital Employed Overview: Onconova Therapeutics Benzinga +10.12%
Jan-25-21 09:49AM	5 Value Stocks In The Healthcare Sector Benzinga
Jan-14-21 08:00AM	Onconova Therapeutics, Inc. to Present at NobleCon17 Virtual Event GlobeNewswire +5.26%
Jan-07-21 09:40AM	Onconova Therapeutics, Inc. Announces $8.7 Million Public Offering GlobeNewswire
Dec-21-20 08:00AM	Onconova Therapeutics Announces FDA Permission for Study to Proceed Under its Investigational New Drug Application for Multi-kinase CDK4/6 Inhibitor ON 123300 GlobeNewswire
Dec-01-20 10:27AM	Return On Capital Employed Overview: Onconova Therapeutics Benzinga +28.45%
Nov-23-20 08:00AM	Onconova Therapeutics Files Investigational New Drug Application for Multi-kinase CDK4/6 Inhibitor ON 123300 GlobeNewswire
Nov-12-20 04:05PM	Onconova Therapeutics Reports Third Quarter 2020 Financial Results and Provides Business Update GlobeNewswire +7.99%
02:30PM	Onconova Therapeutics, Inc. to Host Earnings Call ACCESSWIRE
Nov-05-20 08:00AM	Onconova Therapeutics to Provide Corporate Update and Third Quarter 2020 Financial Results on November 12, 2020 GlobeNewswire
Oct-13-20 08:00AM	Onconova Therapeutics to Present Update During the 2020 BIO Investor Forum Digital Event GlobeNewswire +24.46%
Oct-05-20 09:44AM	5 Value Stocks To Watch In The Healthcare Sector Benzinga
Sep-21-20 10:08AM	Looking Into Onconova Therapeutics's Return On Capital Employed Benzinga +13.08%
08:00AM	Onconova Therapeutics Announces Initiation of a Phase 1 Clinical Trial of ON 123300 in China by Partner HanX Biopharmaceuticals GlobeNewswire
Sep-09-20 08:00AM	Onconova Therapeutics Announces Participation at Upcoming Virtual Events GlobeNewswire +5.01%
Aug-31-20 08:41AM	Overview Of Value Stocks In The Healthcare Sector Benzinga -12.09%
08:00AM	Onconova Therapeutics Announces Election of James J. Marino, JD, MBA as Chairman of the Board of Directors GlobeNewswire
Aug-26-20 06:42PM	After an Unfortunate Surprise, Can Onconova Bounce Back? Analyst Weighs In TipRanks
Aug-25-20 10:06AM	Onconova's Cancer Study Fails to Meet Endpoint, Shares Down Zacks -15.11%
Aug-24-20 11:15AM	Return On Capital Employed Overview: Onconova Therapeutics Benzinga -66.05%
07:30AM	Onconova Therapeutics Announces Topline Results from the Pivotal Phase 3 INSPIRE Trial GlobeNewswire
Aug-17-20 11:46AM	5 Value Stocks To Watch In The Healthcare Sector Benzinga +8.99%
Aug-12-20 04:37PM	Onconova Therapeutics: Q2 Earnings Insights Benzinga
04:05PM	Onconova Therapeutics Highlights Corporate Progress and Reports Second Quarter 2020 Financial Results GlobeNewswire
Aug-07-20 08:00AM	Onconova Therapeutics to Provide Corporate Update and Second Quarter 2020 Earnings on August 12, 2020 GlobeNewswire +7.04%
Aug-04-20 08:00AM	Onconova Therapeutics Announces Compliance with Nasdaq Bid Price Requirement GlobeNewswire
Aug-03-20 11:52AM	Onconova (ONTX) to Report Q2 Earnings: What's in the Offing? Zacks
Jul-29-20 01:30PM	Onconova Therapeutics Announces that the Required Number of Survival Events Has Been Reached for the Pivotal Phase 3 INSPIRE Trial Data Analysis GlobeNewswire +13.27%
Jul-27-20 08:00AM	Onconova Therapeutics Submits Application for Rigosertib to Participate in Federally Funded Human Studies in COVID-19 Disease GlobeNewswire +11.71%
Jul-23-20 08:00AM	Onconova Therapeutics Announces Publication of Preclinical Data Supporting Rigosertibs Mechanism of Action as a Targeted Anticancer Therapy GlobeNewswire
Jul-07-20 08:00AM	Onconova Therapeutics Announces Publication of Phase 1 Results in Leukemia Research Exploring Oral Rigosertib in Combination with Azacitidine in Higher-Risk MDS GlobeNewswire
Jun-23-20 10:43AM	Onconova Initiates Phase I/IIa Study on Lung Cancer Candidate Zacks
08:00AM	Onconova Therapeutics Announces Participation in Noble Capital Markets Investor Webinar GlobeNewswire
Jun-22-20 08:00AM	Onconova Therapeutics Announces the Initiation of a Phase 1/2a Study of Rigosertib plus Nivolumab for the Treatment of KRAS+ Lung Adenocarcinoma GlobeNewswire +6.26%
Jun-12-20 08:00AM	Onconova Therapeutics Announces Presentation at the 25th Congress of the European Hematology Association (EHA) GlobeNewswire
Jun-08-20 08:00AM	Onconova Therapeutics Announces Presentation at BIO Digital 2020 GlobeNewswire
May-28-20 09:44AM	3 Strong Buy Penny Stocks That Offer Massive Potential Gains TipRanks
May-18-20 11:33AM	Edited Transcript of ONTX earnings conference call or presentation 14-May-20 8:30pm GMT Thomson Reuters StreetEvents
May-14-20 04:05PM	Onconova Therapeutics Provides Corporate Update and Reports First Quarter 2020 Financial Results GlobeNewswire
May-11-20 08:00AM	Onconova Therapeutics Announces Virtual Format for 2020 Annual Meeting of Stockholders GlobeNewswire +8.28%
May-07-20 08:00AM	Onconova Therapeutics to Provide Corporate Update and First Quarter 2020 Earnings on May 14, 2020 GlobeNewswire
Apr-27-20 08:00AM	Onconova Therapeutics Strengthens Board of Directors with Nomination of Life Sciences Industry Veteran GlobeNewswire
Apr-07-20 06:40AM	How 3 Philly-area biopharmaceutical firms are working through coronavirus challenges American City Business Journals
Apr-02-20 07:00AM	Edited Transcript of ONTX earnings conference call or presentation 24-Mar-20 8:30pm GMT Thomson Reuters StreetEvents
Mar-24-20 04:05PM	Onconova Therapeutics Announces Completion of Enrollment of Phase 3 INSPIRE Trial, Provides a Corporate Update, and Reports 2019 Financial Results GlobeNewswire +15.58%
Mar-18-20 08:00AM	Onconova Therapeutics to Provide Corporate Update and Full Year 2019 Financial Results GlobeNewswire
Mar-13-20 09:46AM	Will Onconova Therapeutics Continue to Surge Higher? Zacks
Mar-02-20 09:54AM	Onconova (ONTX) to Report Q4 Earnings: What's in Store? Zacks +6.33%
Feb-21-20 10:12AM	The Zacks Analyst Blog Highlights: Onconova Therapeutics, Abeona Therapeutics, Proteostasis Therapeutics, Applied Therapeutics and Ennis Zacks

Onconova Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel products to treat cancer. The company has proprietary targeted anti-cancer agents designed to disrupt specific cellular pathways that are important for cancer cell proliferation. Its novel proprietary multi-kinase inhibitor ON 123300 to target CDK4/6 and other tyrosine kinases. The company's product candidate oral rigosertib, which is in Phase 1 study of rigosertib in combination with a PD-1 inhibitor for patients with progressive K-Ras mutated non-small cell lung cancer; and in Phase 1b/2 for recessive dystrophic epidermolysis bullosa. In addition, it is involved in preclinical work investigating rigosertib in COVID-19. The company has a license agreement with SymBio Pharmaceuticals Limited; and license, development, and commercialization agreement with Pint International SA. Onconova Therapeutics, Inc. was founded in 1998 and is headquartered in Newtown, Pennsylvania.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
OLER ABRAHAM N.	SVP CORP DEV & GEN COUNSEL	Nov 19	Buy	3.16	1,000	3,160	18,514	Nov 23 09:20 AM
OLER ABRAHAM N.	SVP Corp Dev & Gen Counsel	Sep 28	Buy	4.20	2,381	10,000	12,515	Sep 29 08:27 AM
Gelder Mark S. MD	Chief Medical Officer	Sep 28	Buy	4.20	2,381	10,000	2,381	Sep 29 08:25 AM
Fruchtman Steven M	President, Chief Executive Off	Sep 28	Buy	4.20	2,381	10,000	18,130	Sep 28 12:34 PM
MARINO JAMES J	Director	Sep 28	Buy	4.20	5,952	24,998	21,334	Sep 28 12:32 PM
OLER ABRAHAM N.	SVP Corp Dev & Gen Counsel	Feb 16	Buy	1.00	12,000	12,000	152,000	Feb 17 08:57 AM
Guerin Mark Patrick	Chief Financial Officer	Feb 16	Buy	1.00	15,000	15,000	145,213	Feb 17 08:55 AM
Fruchtman Steven M	President, Chief Executive Off	Feb 16	Buy	1.00	20,000	20,000	236,226	Feb 17 08:48 AM
MARINO JAMES J	Director	Feb 16	Buy	1.00	25,000	25,000	230,716	Feb 17 08:46 AM
Shoemaker Mary Teresa	Director	Feb 16	Buy	1.00	13,000	13,000	50,735	Feb 17 08:45 AM
OLER ABRAHAM N.	SVP Corp Dev & Gen Counsel	Dec 11	Buy	0.32	30,000	9,600	140,000	Dec 14 09:00 AM

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience